TY - JOUR
T1 - Efficacia e tollerabilita del Topiramato nella terapia aggiuntiva a lungo termine
T2 - Analisi ad interim dopo quattro anni di trattamento
AU - Canger, R.
AU - Avanzini, G.
AU - Tartara, A.
AU - Durisotti, C.
AU - Guidolin, L.
AU - Binelli, S.
AU - Canafoglia, L.
AU - Sartori, L.
AU - Garofalo, P.
AU - Pozzi, F.
AU - Silenzi, V.
AU - Bertelletti, D.
AU - Di Fazio, M.
AU - Perucca, E.
PY - 1997
Y1 - 1997
N2 - In this open trial efficacy and tolerability of topiramate add-on long term administration have been evaluted in patients with uncontrolled epilepsy of any seizure type 67 patients from 4 Italian centres were studied. TPM was added-on four standard AED's. After TPM titration, a maintenance period with the optimal efficacy dose has been reached in 64 patients. After 3 years, the mean duration of treatment was 9,5 months (± 7,6 d.s), the mean dose of TPM was 274 (± 144) mg/day. The reduction of seizure frequency was obteined in 30% of patients; 75% reduction occurred in 14% and 8% was seizure-free. 19,4% of patients dropped-out for adverse events, 22,4% for inefficacy.
AB - In this open trial efficacy and tolerability of topiramate add-on long term administration have been evaluted in patients with uncontrolled epilepsy of any seizure type 67 patients from 4 Italian centres were studied. TPM was added-on four standard AED's. After TPM titration, a maintenance period with the optimal efficacy dose has been reached in 64 patients. After 3 years, the mean duration of treatment was 9,5 months (± 7,6 d.s), the mean dose of TPM was 274 (± 144) mg/day. The reduction of seizure frequency was obteined in 30% of patients; 75% reduction occurred in 14% and 8% was seizure-free. 19,4% of patients dropped-out for adverse events, 22,4% for inefficacy.
KW - Antiepileptic drugs
KW - Epilepsy
KW - Seizures
KW - Topiramate
UR - http://www.scopus.com/inward/record.url?scp=0031410938&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031410938&partnerID=8YFLogxK
M3 - Articolo
AN - SCOPUS:0031410938
SP - 105
EP - 107
JO - Bollettino - Lega Italiana contro l'Epilessia
JF - Bollettino - Lega Italiana contro l'Epilessia
SN - 0394-560X
IS - 99
ER -